Analysts Set Aardvark Therapeutics, Inc. (NASDAQ:AARD) Target Price at $25.09

Shares of Aardvark Therapeutics, Inc. (NASDAQ:AARD) have received an average recommendation of “Moderate Buy” from the thirteen analysts that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have issued a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $25.0909.

Several equities research analysts recently commented on the company. Oppenheimer dropped their price objective on Aardvark Therapeutics from $35.00 to $21.00 and set an “outperform” rating on the stock in a research report on Monday, March 2nd. Raymond James Financial reissued a “strong-buy” rating and issued a $47.00 target price on shares of Aardvark Therapeutics in a research report on Monday, January 12th. Royal Bank Of Canada cut shares of Aardvark Therapeutics from an “outperform” rating to a “sector perform” rating and lowered their target price for the company from $18.00 to $6.00 in a research note on Monday, March 2nd. BTIG Research dropped their price target on shares of Aardvark Therapeutics from $26.00 to $9.00 and set a “buy” rating on the stock in a report on Monday, March 2nd. Finally, Morgan Stanley reissued an “equal weight” rating and set a $7.00 price objective (down from $29.00) on shares of Aardvark Therapeutics in a report on Monday, March 2nd.

Insider Buying and Selling

In related news, CEO Tien-Li Lee acquired 7,000 shares of Aardvark Therapeutics stock in a transaction dated Thursday, December 11th. The stock was purchased at an average cost of $14.48 per share, for a total transaction of $101,360.00. Following the purchase, the chief executive officer directly owned 1,551,613 shares of the company’s stock, valued at approximately $22,467,356.24. This trade represents a 0.45% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Nelson Sun bought 3,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 11th. The stock was bought at an average cost of $14.40 per share, for a total transaction of $43,200.00. Following the completion of the acquisition, the chief financial officer owned 108,484 shares in the company, valued at $1,562,169.60. This trade represents a 2.84% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.

Institutional Trading of Aardvark Therapeutics

Hedge funds have recently bought and sold shares of the stock. UBS Group AG increased its position in Aardvark Therapeutics by 5.4% in the third quarter. UBS Group AG now owns 54,728 shares of the company’s stock worth $727,000 after buying an additional 2,804 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Aardvark Therapeutics during the 2nd quarter valued at about $42,000. Bank of America Corp DE grew its stake in shares of Aardvark Therapeutics by 72.9% during the 2nd quarter. Bank of America Corp DE now owns 7,989 shares of the company’s stock valued at $108,000 after acquiring an additional 3,369 shares during the period. China Universal Asset Management Co. Ltd. bought a new position in shares of Aardvark Therapeutics during the 4th quarter valued at approximately $47,000. Finally, Persistent Asset Partners Ltd purchased a new stake in Aardvark Therapeutics in the 4th quarter worth approximately $56,000.

Aardvark Therapeutics Trading Up 4.1%

Aardvark Therapeutics stock opened at $6.09 on Friday. The firm has a market cap of $132.58 million and a price-to-earnings ratio of -2.87. The stock has a fifty day simple moving average of $12.55 and a two-hundred day simple moving average of $11.99. Aardvark Therapeutics has a 12 month low of $4.74 and a 12 month high of $17.94.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.